Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Therapy for End-of-Life Distress
NCT05958758Phase 1Unknown
- Sponsor
- Roots to Thrive
- Start
- Sep 2023
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in terminal agitation, sponsored by Roots to Thrive. Primary endpoints: Adverse events (AEs), serious adverse events (SAEs) and treatment emergent adverse events (TEAEs), Safety Monitoring: Biomedical measures - Pregnancy testing at Week 5 and 2 more. Status: unknown.
02
Drugs
psilocybin
03
Conditions
terminal agitation
Beyond the preview
Go deeper on NCT05958758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05958758.